Use of live viral vaccines after HCT: Still a lot to learn.
HCT
live vaccines
measles
mumps
rubella
serology
yellow fever
Journal
Transplant infectious disease : an official journal of the Transplantation Society
ISSN: 1399-3062
Titre abrégé: Transpl Infect Dis
Pays: Denmark
ID NLM: 100883688
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
revised:
05
02
2023
received:
28
10
2022
accepted:
12
02
2023
medline:
11
4
2023
pubmed:
4
3
2023
entrez:
3
3
2023
Statut:
ppublish
Résumé
Revaccination program after HCT is necessary due to the loss of lifelong immunity acquired by previous vaccination or infections. The program is complex and even in a favourable scenario, it takes more than 2 years to be completed. As the complexity of HCT increases (alternative donors, diversity of monoclonal antibodies), studies evaluating the response to vaccination in this population are welcome, especially those that evaluate live attenuated vaccines given their scarcity. Furthermore, measles, mumps, rubella and even yellow fever, and poliomyelitis outbreaks have perplexed infectious diseases clinicians and epidemiologists globally, most of them due to the decline in vaccination coverage rates in children and adults, because of the growth of antivaccine movements around the world. The study of Lin et al. adds important information about measles, mumps and rubella vaccination after HCT.
Substances chimiques
Viral Vaccines
0
Measles-Mumps-Rubella Vaccine
0
Vaccines, Attenuated
0
Vaccines, Combined
0
Antibodies, Viral
0
Types de publication
Editorial
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14044Informations de copyright
© 2023 Wiley Periodicals LLC.
Références
da Silva PM, da Silva ÉM, Simioni AJ, de Souza MP, Colturato VAR, Machado CM. Difficulties in the revaccination program of hematopoietic stem cell transplantation recipients. Rev Inst Med Trop Sao Paulo. 2017;59(2):87-98.
Cordonnier C, Einarsdottir S, Cesaro S, et al. Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis. 2019;19(6):e200-e212.
Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis [Internet]. 2014;58(3):309-318. http://cid.oxfordjournals.org/lookup/doi/10.1093/cid/cit816
de Vigilância em Saúde S, da Saúde M. Manual Dos Centros de Referencia para Imunobiológicos Especiais. 5a ed. Ministério da Saúde; 2019. https://portalarquivos2.saude.gov.br/images/pdf/2019/dezembro/11/manual-centros-referencia-imunobiologicos-especiais-5ed.pdf
Maiolino MG, Carlesse F, Ramos JF. Prevention and treatment of infectious complications post HSCT. JBMTCT [Internet]. 2021;2(1):197-217. Available from: https://www.jbmtct.com.br/seer/index.php/jbmtct/article/view/82
Ljungman P, Fridell E, Lönnqvist B, et al. Efficacy and safety of vaccination of marrow transplant recipients with a live attenuated measles, mumps, and rubella vaccine. J Infect Dis. 1989;159(4):610-615.
Machado CM, de Souza V, Sumita LM, da Rocha I, Dulley FL, Pannuti CS. Early measles vaccination in bone marrow transplant recipients. Bone Marrow Transplant [Internet]. 2005;35(8):787-791. Available from: http://www.nature.com/articles/1704878
Sicre De Fontbrune F, Arnaud C, Cheminant M, et al. Immunogenicity and safety of yellow fever vaccine in allogeneic hematopoietic stem cell transplant recipients after withdrawal of immunosuppressive therapy. J Infect Dis. 2018;217(3):494-497.
de Testa LHA, Simioni AJ, Colturato I, et al. Differences in the compliance with yellow fever and measles vaccines in the revaccination programa after hematopoietic stem cell transplantation. Proceedings of 2020 anual meeting of the Brazilian Society of Bone Marrow Transplantation. Journal of Bone Marrow Transplantation and Cellular Therapy. 2020;298. https://www.jbmtct.com.br/seer/index.php/jbmtct/issue/view/4
Dubé È, Ward JK, Verger P, Macdonald NE. Vaccine hesitancy, acceptance, and anti-vaccination: trends and future prospects for public health. Annu Rev Public Health. 2020;42:175-191.
Lin R, Anderson A, Morris M, Raja M, Komanduri K, Camargo J. Successful restoration of protective immunity against measles, mumps, and rubella following MMR vaccination in adult hematopoietic cell transplant recipients - TID-22-S-047.R1. Transpl Infect Dis. 2023.
Shelton JD, Jacobson JE, Orenstein WA, Schulz KF, Donnell HD. Measles vaccine efficacy: influence of age at vaccination vs. duration of time since vaccination. Pediatrics. 1978;62(6):961-964.